Short Interest in Silexion Therapeutics Corp (NASDAQ:SLXN) Drops By 29.7%

Silexion Therapeutics Corp (NASDAQ:SLXN) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 78,920 shares, a drop of 29.7% from the November 30th total of 112,215 shares. Based on an average trading volume of 51,039 shares, the days-to-cover ratio is presently 1.5 days. Currently, 2.7% of the company’s shares are sold short. Currently, 2.7% of the company’s shares are sold short. Based on an average trading volume of 51,039 shares, the days-to-cover ratio is presently 1.5 days.

Silexion Therapeutics Stock Down 2.8%

Shares of NASDAQ:SLXN traded down $0.07 during trading on Monday, hitting $2.23. The stock had a trading volume of 21,647 shares, compared to its average volume of 402,493. The company has a market capitalization of $6.96 million, a PE ratio of -0.20 and a beta of -0.06. The company has a quick ratio of 3.97, a current ratio of 3.97 and a debt-to-equity ratio of 0.22. The firm’s fifty day moving average is $2.85 and its 200 day moving average is $6.37. Silexion Therapeutics has a 12 month low of $2.13 and a 12 month high of $51.75.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share for the quarter, topping the consensus estimate of ($3.40) by $0.52.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on SLXN shares. Wall Street Zen lowered shares of Silexion Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, October 8th. Zacks Research raised Silexion Therapeutics to a “hold” rating in a research note on Tuesday, December 16th. Finally, Litchfield Hills Research initiated coverage on Silexion Therapeutics in a report on Monday, December 15th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $75.00.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.